Archives: Speakers

Mark Laney has more than 20 years of experience with software in the Life Sciences industry focused on delivering the right solutions for customers. As Sr Director, Sales Engineering & Partnerships, he is tasked with solving customer challenges using the breadth of functionality and flexibility of Zelta’s unified clinical data management solution while facilitating partnerships with complimentary industry leading vendors to offer customers a robust technology solution for their clinical needs.

Karlo Svrze, MSc, FMVA® is a life‑sciences professional at BD (Becton, Dickinson & Co.) with a background spanning clinical research, diagnostics, and translational healthcare. He worked as a research scientist in regenerative medicine and biomolecular research. His current focus lies at the interface of clinical practice and diagnostics, supporting the translation of scientific and clinical requirements into robust, scalable preanalytical solutions across complex clinical trial environments.

Julie Martin, MSc, Lean Certified, CEO is a 19-year industry veteran who has led Scimega as CEO for 7 years. Her passion for Scimega’s business and team stems from knowing its expert oncology clinical development services add distinct value to industry stakeholders at a time when it’s needed most. As CEO, Julie’s vision is to secure the company’s long-term success by leveraging her in-depth industry expertise and business acumen. She equates that success with setting a clear vision for the organization’s continued sense of purpose. Her leadership, and collaboration with the managing Board of Directors, combined ensures the business excellence upon which Scimega has built its reputation. Julie plays a vital role in promoting Scimega’s expertise and showcasing Canada’s attributes as a formidable partner in global oncology drug development with an evolving Lean methodology.

Jodi is a growth-focused medical device executive and consultant with nearly 15 years of experience leading commercialization, global marketing, and go-to-market strategy for startups and growth-stage organizations. She has a proven track record of launching disruptive technologies, accelerating adoption in complex clinical markets, and building the commercial foundation for successful acquisitions and IPOs and sustained revenue growth. She has deep expertise across electrophysiology, cardiology, spine, and patient monitoring, including AI-enabled platforms, reimbursement, and KOL-driven market development.

Mindy Hurd brings over 30 years of experience in the pharmaceutical research industry, with the majority of her career spent in leadership roles at global, full‑service CROs. As a General Partner at ICON, she focuses on successful operational delivery and executive‑level support for biotech clients navigating the complexities of clinical development across therapeutic areas. Mindy has deep expertise across the drug development lifecycle, with particular strength in cross‑functional leadership, risk management, process improvement, and governance oversight to ensure high‑quality program delivery.